18 September 2019 | News
To develop, manufacture and commercialize TSD-001 for all indications in Korea
image credit- shuttershock.com
LIPAC Oncology LLC and Huons Co., Ltd have announced that they have entered into an exclusive licensing agreement to develop, manufacture and commercialize TSD-001 for all indications in Korea. Huons is making an upfront payment and future milestone payments to LIPAC based on specific development, regulatory and commercial milestones. Huons will also make double-digit royalty payments based on sales.
TSD-001 is a proliposomal intravesical paclitaxel formulation (PLIP), currently in development for intravesical administration in the treatment of non-muscle invasive bladder cancer (NMIBC). NMIBC is a common and highly recurrent disease that can often be difficult to treat. If approved, TSD-001 would be the first chemotherapeutic agent approved by the U.S. Food and Drug Administration for this indication in almost two decades. Additional indications covered by the agreement include upper tract urothelial carcinoma, stage II/III ovarian cancer and peritoneal carcinoma.
"We are excited to potentially bring TSD-001 to patients living with bladder cancer in Korea," said Michael Oefelein, M.D., Chief Medical Officer of LIPAC. "Having treated bladder cancer for more than 23 years, it is very clear that new treatment options and more effective delivery systems could help improve both clinical outcomes and quality of life."
"This collaboration is the first of many we envisage under our global development strategy," said Will Robberts, President of LIPAC. "We believe that regional partnerships with strong companies such as Huons are essential to navigate the local subtleties of commercialization in countries outside of the United States."
The parties will form a Joint Development Committee to collaborate on the clinical development of TSD-001 in Korea and other partnering opportunities.
"We look forward to collaborating closely with LIPAC given their deep experience with TSD-001 and their proprietary proliposomal delivery platform," said Keyan UM, President and CEO of Huons. "We believe patients in Korea will benefit from a chemotherapy that targets the site of their disease."